Overall survival, Hazard ratio, All population

Age	Age<65years (N=81)	reference		-			
	Age≥65years (N=90)	2.57 (1.006 - 6.57)					0.048 *
Smoking	Never-smoker (N=43)	reference					
	(Ex-) Smoker (N=128)	2.03 (0.741 - 5.54)				-	0.169
ECOG PS	ECOG0-1 (N=154)	reference					
	ECOG2 (N=17)	2.11 (0.393 - 11.33)		· · · · · · · · · · · · · · · · · · ·			0.383
EGFR	Wild (N=55)	reference					
	Mutant (N=22)	0.39 (0.120 - 1.29)	·				0.125
Stage	Stage II (N=17)	reference		-			
	Stage IIIA (N=47)	0.98 (0.164 - 5.90)					0.986
	Stage IIIB (N=82)	2.30 (0.434 - 12.17)		H	-		0.328
	Stage IIIC (N=25)	12.90 (2.221 - 74.96)			t.		1 0.004 **
Chemotherapy regimen	Others (N=44)	reference		•			
	TP regimen (N=127)	2.23 (0.798 - 6.23)			-		0.126
Use of durvalumab	CCRT alone (N=82)	reference					
	CCRT+Durvalumab (N=89)	0.24 (0.088 - 0.67)	-				0.006 **
	(N=171)	0.99 (0.959 - 1.01)					0.269

S2 Fig. Multivariate analysis of overall survival in patients with concurrent chemoradiotherapy for unresectable locally advanced non–small cell lung cancer. ECOG PS, European Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; DLCO, diffusing capacity of the lung for CO.